Vascular biosynthesis of nitric oxide: Effect on hemostasis and fibrinolysis

Transfusion Clinique et Biologique

Volumn 6, Issue 6, 1999, Pages 355-363

  Schini Kerth, V B ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Endothelial cell; Hemostasis; Nitric oxide; NO synthase; Vascular homeostasis

Indexed keywords

HEMOGLOBIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

BIOSYNTHESIS; BLOOD VESSEL TONE; CELL MIGRATION; CELL PROLIFERATION; CHEMICAL REACTION; CONFERENCE PAPER; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HEMOSTASIS; HOMEOSTASIS; HUMAN; PROTEIN SYNTHESIS; THROMBOCYTE FUNCTION;

EID: 0033380349     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1246-7820(00)88980-6     Document Type: Conference Paper

References (39)

1. Vanhoutte PM. Endothelial dysfunction and vascular disease. In: Panza JA, Cannon RO III, eds. Endothelium, Nitric Oxide, and Atheroslerosis. Armonk, NY: Futura Publishing Co, Inc; 1999. p. 79-95.
2. Fleming I, Busse R. Vascular effects of NO. In: Goligorsky M, Gross SS, eds. Nitric Oxide and the Kidney: Physiology and Pathophysiology. New York: Chapman and Hall; 1997. p. 161-75.
3. Schini-Kerth VB, Vanhoutte PM. Nitric oxide synthases in vascular cells. Exp Physiol 1995; 80: 885-905.
4. Shaul PW, Smart EJ, Robinson LJ, German Z, Yuhanna IS, Ying Y, Acylation targets endothelial nitric-oxide synthase to plasmalemmal caveolae. J Biol Chem 1996; 271: 6518-22.
5. Garcia-Cardena G, Oh P, Liu J, Schnitzer JE, Sessa WC. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: Implications for nitric oxide signalling. Proc Natl Acad Sci USA 1996; 93: 6448-53.
6. Luscher TF, Vanhoutte Pm, Eds. The Endothelium: ModulaTor of Cardiovascular Function. Boca Raton, FL: CRC Press; 1990.
7. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
8. Furchgott RF. The requirement for endothelial cells in the relaxation of arteries by acetylcholine and some other vasodilators. Trends Pharmacol Sci 1981; 2: 173-6.
9. Kuchan MJ, Frangos JA. Role of calcium and calmodulin in flow-induced nitric oxide production in endothelial cells. Am J Physiol. 1994; 266: C628-C36.
10. Ayajiki K, Kindermann M, Hecker M, Fleming I, Busse R. Intracellular ph and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells. Circ Res 1996; 78: 750-8.
11. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by akt-dependent phosphorylation. Nature 1999; 399: 601-5.
12. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Regulation of endothelium-derived nitric oxide production by the protein kinase akt. Nature 1999; 399: 597-601.
13. Förstermann U, Boissel JP, Kleinert H. Expressional control of the constitutive isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998; 12: 790.
14. Bouloumié A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 1999; 41: 773-80.
15. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-42.
16. Kronemann N, Nockher WA, Busse R, Schini-Kerth VB. Growth-inhibitory effect of cyclic GMP- and cyclic AMP-dependent vasodilators on rat vascular smooth muscle cells: Effect on cell cycle and cyclin expression. Br J Pharmacol 1999; 126: 349-57.
17. Tabuchi A, Sano K, Oh E, Tsuchiya T, Tsuda M. Modulation of AP-1 activity by nitric oxide (NO) in vitro: No-mediated modulation of AP-1. FEBS Lett 1994; 351: 123-7.
18. Peng HB, Libby P, Liao JK. Induction and stabilization of ikappabalpha by nitric oxide mediates inhibition of nfkappab. J Biol Chem 1995; 270: 14214-9.
19. Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cgmp in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987; 148: 1482-9.
20. Sneddon JM, Vane JR. Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci USA 1988; 85: 2800-4.
21. De Graaf JC, Banga JD, Moncada S, Palmer RMJ, De Groot PG, Sixma JJ. Nitric oxide as an inhibitor of platelet adhesion under flow conditions. Circulation 1992; 85: 2284-90.
22. Azuma H, Ishikawa M, Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986; 88: 411-5.
23. Busse R, Lückhoff A, Bassenge E. Endothelium-derived relaxant factor inhibits platelet activation. Naunyn-schmiedeberg's Arch Pharmacol 1987; 336: 566-71.
24. Houston DS, Robinson P, Gerrard JM. Inhibition of intravascular platelet aggregation by endothelium-derived relaxing factor: Reversal by red blood cells. Blood 1990; 76: 953-8.
25. Pohl U, Busse R. EDRF increases cyclic GMP in platelets during the passage through the coronary vascular bed. Circ Res 1989; 65: 1798-1803.
26. Stamler JS, Vaughan DE, Loscalzo J. Synergistic disaggregation of platelets by tissue-type plasminogen activator. Prostaglandin E1, and nitroglycerin. Circ Res 1989; 65: 796-804.
27. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639-46.
28. Broekman MJ, Eiroa AM, Marcus AJ. Inhibition of human platelet reactivity by endothelium-derived relaxing factor from human umbilical vein endothelial cells in suspension: Blockade of aggregation and secretion by an aspirine-insensitive mechanism. Blood 1991; 78: 1033-40.
29. Mendelsohn ME, O'Neill S, George D, Loscalzo J. Inhibition of fibrinogen binding to human platelets by s-nitroso-n-acetylcysteine. J Biol Chem 1990; 265: 19028-34.
30. Durante W, Kroll MH, Vanhoutte PM, Schafer AI. Endothelium-derived relaxing factor inhibits thrombin-induced platelet aggregation by inhibiting platelet phospholipase C. Blood 1992; 79: 110-16.
31. Geiger J, Nolte C, Butt E, Sage SO, Walter U. Role of cgmp and cgmp-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets. Proc Natl Acad Sci USA 1992; 89: 1031-5.
32. Gerlach M, Keh D, Bezold G, Spielmann S, Küurer I, Peter RU, Nitric oxide inhibits tissue factor synthesis and activity in human monocytes by prior formation of peroxy-nitrite. Intensive Care Med 1998; 24: 1199-1208.
33. Lidbury PS, Korbut R, Vane JR. Sodium nitroprusside modulates the fibrinolytic system in the rabbit. Br J PharmaCol 1990; 101: 527-30.
34. Grodzinska L, Hafner G, Darius H. Effect of molsidomine on t-PA and PAI activity in man: A double blind, placebo controlled study. Thromb Haemost 1990; 64: 485.
35. Drummer C, Lüdke S, Spannagl M, Schramm W, Gerzer R. The nitric oxide SIN-1 is a potent inhibitor of plasminogen activator inhibitor release from stimulated platelets. Thromb Res 1991; 63: 553-6.
36. Newby DE, Wright RA, Dawson P, Ludlam CA, Boon NA, Fox KAA, The l-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. Cardiovasc Res 1998; 38: 485-92.
37. Simon DI, Stamler JS, Loh E, Loscalzo J, Francis SA, Creager MA. Effect of nitric oxide synthase inhibition on bleeding time in humans. J Cardiovasc Pharmacol 1995; 26: 339-42.
38. Jia L, Bonaventura C, Bonaventura J, Stamler JS. S-nitroso-haemoglobin: A dynamic activity of blood involved in vascular control. Nature 1996; 380: 221-6.
39. Stamler JS, Jia L, Eu JP, McMahon TJ, Demchenko IT, Bonaventura J, Blood flow regulation by s-nitrosohemoglobin in the physiological oxygen gradient. Science 1997; 276: 2034-7.